The injection makes the waist smaller relative to the hips, giving a less 'apple-shaped' body and more 'pear-shaped' proportions.
Scientific Claim
Tesamorelin (2 mg subcutaneous daily) reduces waist-hip ratio by a statistically significant amount in HIV-infected adults on antiretroviral therapy with abdominal fat accumulation over 6 months, indicating improved body fat distribution.
Original Statement
“Trunk fat (P < 0.001), waist circumference (P = 0.02), and waist-hip-ratio (P = 0.001) improved, with no change in limb or abdominal SC fat.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The RCT design and strong statistical significance (P = 0.001) support definitive causal language for this clinically relevant anthropometric change.
Evidence from Studies
Supporting (1)
Unknown Title
The study found that a daily shot of tesamorelin helped HIV patients lose belly fat and improve their waist-to-hip shape over six months, without harming their blood sugar, and the results were strong and reliable.